|
1
|
Luo H, Xia X, Huang LB, An H, Cao M, Kim
GD, Chen HN, Zhang WH, Shu Y, Kong X, et al: Pan-cancer single-cell
analysis reveals the heterogeneity and plasticity of
cancer-associated fibroblasts in the tumor microenvironment. Nat
Commun. 13:66192022. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mhaidly R and Mechta-Grigoriou F: Role of
cancer-associated fibroblast subpopulations in immune infiltration,
as a new means of treatment in cancer. Immunol Rev. 302:259–272.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen Y, McAndrews KM and Kalluri R:
Clinical and therapeutic relevance of cancer-associated
fibroblasts. Nat Rev Clin Oncol. 18:792–804. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Broz MT, Ko EY, Ishaya K, Xiao J, De
Simone M, Hoi XP, Piras R, Gala B, Tessaro FHG, Karlstaedt A, et
al: Metabolic targeting of cancer associated fibroblasts overcomes
T-cell exclusion and chemoresistance in soft-tissue sarcomas. Nat
Commun. 15:24982024. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wu F, Yang J, Liu J, Wang Y, Mu J, Zeng Q,
Deng S and Zhou H: Signaling pathways in cancer-associated
fibroblasts and targeted therapy for cancer. Signal Transduct
Target Ther. 6:2182021. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ueno H, Kajiwara Y, Ajioka Y, Sugai T,
Sekine S, Ishiguro M, Takashima A and Kanemitsu Y:
Histopathological atlas of desmoplastic reaction characterization
in colorectal cancer. Jpn J Clin Oncol. 51:1004–1012. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sandberg TP, Stuart MPME, Oosting J,
Tollenaar RAEM, Sier CFM and Mesker WE: Increased expression of
cancer-associated fibroblast markers at the invasive front and its
association with tumor-stroma ratio in colorectal cancer. BMC
Cancer. 19:2842019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hu Q, Wang Y, Yao S, Mao Y, Liu L, Li Z,
Chen Y, Zhang S, Li Q, Zhao Y, et al: Desmoplastic reaction
associates with prognosis and adjuvant chemotherapy response in
colorectal cancer: A multicenter retrospective study. Cancer Res
Commun. 3:1057–1066. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Akimoto N, Väyrynen JP, Zhao M, Ugai T,
Fujiyoshi K, Borowsky J, Zhong R, Haruki K, Arima K, Lau MC, et al:
Desmoplastic reaction, immune cell response, and prognosis in
colorectal cancer. Front Immunol. 13:8401982022. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sueyama T, Kajiwara Y, Mochizuki S,
Shimazaki H, Shinto E, Hase K and Ueno H: Periostin as a key
molecule defining desmoplastic environment in colorectal cancer.
Virchows Arch. 478:865–874. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wilson WR and Hay MP: Targeting hypoxia in
cancer therapy. Nat Rev Cancer. 11:393–410. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chi JT, Wang Z, Nuyten DS, Rodriguez EH,
Schaner ME, Salim A, Wang Y, Kristensen GB, Helland A,
Børresen-Dale AL, et al: Gene expression programs in response to
hypoxia: Cell type specificity and prognostic significance in human
cancers. PLoS Med. 3:e472006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Uemura M, Yamamoto H, Takemasa I, Mimori
K, Hemmi H, Mizushima T, Ikeda M, Sekimoto M, Matsuura N, Doki Y
and Mori M: Jumonji domain containing 1A is a novel prognostic
marker for colorectal cancer: In vivo identification from hypoxic
tumor cells. Clin Cancer Res. 16:4636–446. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Uemura M, Yamamoto H, Takemasa I, Mimori
K, Mizushima T, Ikeda M, Sekimoto M, Doki Y and Mori M:
Hypoxia-inducible adrenomedullin in colorectal cancer. Anticancer
Res. 31:507–514. 2011.PubMed/NCBI
|
|
15
|
Noda T, Yamamoto H, Takemasa I, Yamada D,
Uemura M, Wada H, Kobayashi S, Marubashi S, Eguchi H, Tanemura M,
et al: PLOD2 induced under hypoxia is a novel prognostic factor for
hepatocellular carcinoma after curative resection. Liver Int.
32:110–118. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yamamoto H, Tei M, Uemura M, Takemasa I,
Uemura Y, Murata K, Fukunaga M, Ohue M, Ohnishi T, Ikeda K, et al:
Ephrin-A1 mRNA is associated with poor prognosis of colorectal
cancer. Int J Oncol. 42:549–555. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wada H, Yamamoto H, Kim C, Uemura M, Akita
H, Tomimaru Y, Hama N, Kawamoto K, Kobayashi S, Eguchi H, et al:
Association between ephrin-A1 mRNA expression and poor prognosis
after hepatectomy to treat hepatocellular carcinoma. Int J Oncol.
45:1051–1058. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Munakata K, Uemura M, Takemasa I, Ozaki M,
Konno M, Nishimura J, Hata T, Mizushima T, Haraguchi N, Noura S, et
al: SCGB2A1 is a novel prognostic marker for colorectal cancer
associated with chemoresistance and radioresistance. Int J Oncol.
44:1521–1528. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kawai K, Uemura M, Munakata K, Takahashi
H, Haraguchi N, Nishimura J, Hata T, Matsuda C, Ikenaga M, Murata
K, et al: Fructose-bisphosphate aldolase A is a key regulator of
hypoxic adaptation in colorectal cancer cells and involved in
treatment resistance and poor prognosis. Int J Oncol. 50:525–534.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Schwörer S, Cimino FV, Ros M, Tsanov KM,
Ng C, Lowe SW, Carmona-Fontaine C and Thompson CB: Hypoxia
potentiates the inflammatory fibroblast phenotype promoted by
pancreatic cancer Cell-derived cytokines. Cancer Res. 83:1596–1610.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hashiguchi Y, Muro K, Saito Y, Ito Y,
Ajioka Y, Hamaguchi T, Hasegawa K, Hotta K, Ishida H, Ishiguro M,
et al: Japanese society for cancer of the colon and rectum (JSCCR)
guidelines 2019 for the treatment of colorectal cancer. Int J Clin
Oncol. 25:1–42. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Elyada E, Bolisetty M, Laise P, Flynn WF,
Courtois ET, Burkhart RA, Teinor JA, Belleau P, Biffi G, Lucito MS,
et al: Cross-species single-cell analysis of pancreatic ductal
adenocarcinoma reveals antigen-presenting cancer-associated
fibroblasts. Cancer Discov. 9:1102–1123. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bouillon R, Schuit F, Antonio L and
Rastinejad F: Vitamin D binding protein: A historic overview. Front
Endocrinol (Lausanne). 10:9102019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kim H, Lipsyc-Sharf M, Zong X, Wang X, Hur
J, Song M, Wang M, Smith-Warner SA, Fuchs C, Ogino S, et al: Total
vitamin d intake and risks of Early-onset colorectal cancer and
precursors. Gastroenterology. 161:1208–1217.e9. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Goltzman D, White J and Kremer R: Studies
of the effects of 1, 25-dihydroxyvitamin D on skeletal and calcium
homeostasis and on inhibition of tumor cell growth. J Steroid
Biochem Mol Biol. 76:43–47. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yang C, Tian Y, Zhao F, Chen Z, Su P, Li Y
and Qian A: Bone microenvironment and osteosarcoma metastasis. Int
J Mol Sci. 21:69852020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Clézardin P, Coleman R, Puppo M, Ottewell
P, Bonnelye E, Paycha F, Confavreux CB and Holen I: Bone
metastasis: Mechanisms, therapies, and biomarkers. Physiol Rev.
101:797–855. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Motokura T, Endo K, Kumaki K, Ogata E and
Ikeda K: Neoplastic transformation of normal rat embryo fibroblasts
by a mutated p53 and an activated ras oncogene induces parathyroid
hormone-related peptide gene expression and causes hypercalcemia in
nude mice. J Biol Chem. 270:30857–30861. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li XL, Zhou J, Chen ZR and Chng WJ: P53
mutations in colorectal cancer-molecular pathogenesis and
pharmacological reactivation. World J Gastroenterol. 21:84–93.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kanno K, Akutsu T, Ohdaira H, Suzuki Y and
Urashima M: Effect of Vitamin D supplements on relapse or death in
a p53-Immunoreactive subgroup with digestive tract cancer: Post hoc
analysis of the AMATERASU randomized clinical trial. JAMA Netw
Open. 6:e23288862023. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mundy GR and Edwards JR: PTH-related
peptide (PTHrP) in hypercalcemia. J Am Soc Nephrol. 19:672–675.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhao M, Wang S, Zuo A, Zhang J, Wen W,
Jiang W, Chen H, Liang D, Sun J and Wang M: HIF-1α/JMJD1A signaling
regulates inflammation and oxidative stress following hyperglycemia
and Hypoxia-induced vascular cell injury. Cell Mol Biol Lett.
26:402021. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yang Y, Wu J, Zhu H, Shi X, Liu J, Li Y
and Wang M: Effect of hypoxia-HIF-1α-periostin axis in thyroid
cancer. Oncol Rep. 51:572024. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kerk SA, Papagiannakopoulos T, Shah YM and
Lyssiotis CA: Metabolic networks in mutant KRAS-driven tumours:
Tissue specificities and the microenvironment. Nat Rev Cancer.
21:510–525. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhu G, Pei L, Xia H, Tang Q and Bi F: Role
of oncogenic KRAS in the prognosis, diagnosis and treatment of
colorectal cancer. Mol Cancer. 20:1432021. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Brown BA, Myers PJ, Adair SJ, Pitarresi
JR, Sah-Teli SK, Campbell LA, Hart WS, Barbeau MC, Leong K, Seyler
N, et al: A Histone Methylation-MAPK signaling axis drives durable
Epithelial-mesenchymal transition in hypoxic pancreatic cancer.
Cancer Res. 84:1764–180. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Pitarresi JR, Norgard RJ, Chiarella AM,
Suzuki K, Bakir B, Sahu V, Li J, Zhao J, Marchand B, Wengyn MD, et
al: PTHrP drives pancreatic cancer growth and metastasis and
reveals a new therapeutic vulnerability. Cancer Discov.
11:1774–1791. 2021. View Article : Google Scholar : PubMed/NCBI
|
